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ABSTRACT. A group of trisubstituted pyrazoles containing thiophen, 2-alkyloxypyridine and thieno[2,3-
d]pyrimidine heterocycles were synthesized in a study for possible analgesic agents. The desired products were 
obtained by reaction of 2-((1-(3-chlorophenyl)-3-(4-methoxyphenyl)-1H-pyrazol-4-yl)methylene)malononitrile 
with sulfur in presence of TEA, followed by treatment with different reagents. Newer products were examined for 
their analgesic properties, among them, analog 7 showed significant analgesic effects in comparison with 
reference medicines activity. 
 
KEY WORDS: Trisubstituted pyrazoles, Thiophene, Alkyloxypyridine, Fused pyrimidine, Analgesic activities 
 
INTRODUCTION 
 
Pyrazole compounds have an interesting therapeutic effect. Due to the large amount of drugs 
including this heterocyclic compound, the pharmaceutical properties of the ring were the topic 
of medicinal studies. Celecoxib and its derivatives are analgesic medicines with a pyrazole 
nucleus (Figure 1). Diverse bioactive molecules are developed by pyrazole derivatives such as 
antibacterial, anti-inflammatory, antifungal, antiviral, antimicrobial,and anti-hyperglycemic 
properties [1-10]. Moreover, pyrazole-based heterocycles as thiophenes, 2-alkyloxypyridines 
and thieno[2,3-d]pyrimidines have been given more attention due to their useful therapeutic 
fields including, muscle relaxing, antitumor, anti-depressant, antimicrobial, antidiabetic, anti-
tubercular, antioxidant, HIV reverse transcriptase inhibitors and also possess significant 
vasodilation activities [11-17]. They also demonstrated strong anti-inflammatory action with 
low GIT toxicity and analgesic impacts [18-24]. In the same way, and in the continuing work on 
synthesis of biologically active heterocycles based pyrazoles [25-29], we focused in this study 
on designing of new molecules carrying pyrazole substituents as hybrids with various 
heterocycles aiming to get potent candidates with analgesic properties. 
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Figure 1. Structure of marketed pyrazole drugs and synthesized compound (7). 
 
EXPERIMENTAL 
 
Electrothermal device 9100 has identified melting points. Elementary microanalysis using Vario 
Elemental was acceptable and performed. The spectrophotometer Shimadzu 435 IR was used to 
operate infrared spectrum (KBr pellets technique). Varian Gemini 500 MHz NMR 
Spectrophotometer was used for recording 1H, 13C NMR spectra DMSO-d6 with TMS as an 
internal reference. Hewlett Packard 5988 Spectrometer registered the mass spectrum (70 eV). 
 
Animals 
 
The study included albino mice (25-30 g) and wistar rats (150-200 g). Mice and rats used for 
this experiment were bought from the animal breeding laboratory, NRC, Egypt. Whole animals 
have been preserved with free access to animal feed under the lights of 12 hours. Prior to 
testing, the animals were adapted for a week to the lab environment. In line with the Ethics 
Committee, the animal protocol was performed of (NRC), Egypt. 
 
Central analgesic activity (hot plate test) 
 
By using hot-plate appliance, the central analgesic effects of the examined compounds were 
achieved. Twelve groups were collected with 6 animals each. The first group was used as 
(normal control) and the second group was used as (reference) received the vehicle at a dose of 
(5 mL/kg) and tramadol (40 mg/kg) orally, respectively. Dose levels of (20 mg/kg) were taken 
orally to the remaining groups from 3rd to 12th. Within an hour of treatment, mice were placed 
on a hot plate at 53 ± 0.5 oC separately. On mice lick the fore or hind paw or spring away from 
the location, the reaction time of the thermal stimulus was determined. After oral administration 
of tested compounds, the response time was recorded (0, 30, 60 and 90 min). The time off for 
heat stimulation reaction was 60 s to prevent damaging the tissue of the mouse fingers. 
 
Peripheral analgesic activity (Writhing test) 
 
Acetic acid writhing test was achieved on mice and aspirin was used as a reference control. 72 
mice, each with six animals, have been divided into 12 sets. Vehicle (5 mL/kg) and aspirin (150 
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mg/kg) were used orally for treatment of mice of 1st group (control) and 2nd group (reference).  
Dose of (20 mg/kg) of the 3rd to 12th groups of mouse was administered orally to the test 
compound. Writhes were produced after a 30 min dose of intraperitoneal injection of acetic acid 
(0.7% aqueous acetic acid) at a dosage of (10 mL/kg). Mice were then placed in transparent 
boxes and the mean number of Writhes was calculated for each group in comparison to control 
group during 20 min according to the equation: 
Protection (%) = [(Control mean - Treated mean)/Control mean] x 100 
 
2-Amino-4-(1-(3-chlorophenyl)-3-(4-methoxyphenyl)-1H-pyrazol-4-yl)thiophene-3-carbonitrile 
(2) 
 
In ethyl alcohol (50 mL), an equimolar mix (0.03 mol) of both ylidenemalononitrile 1 and sulfur 
were added and the mix was cooled to 10 oC, followed by dropwise addition of TEA (0.03 mol). 
The reaction mixture was heated for 2 h at 80 oC, and cooled afterwards. The solid residues 
generated were ethanol crystallized. Yield: 67%, m.p. 209-211 oC. IR (KBr, cm-1) ν: 3386 
(NH2), 2210 (CN). 
1H NMR (DMSO-d6): δ 3.81 (s, 3H, OCH3), 4.52 (s, 2H, NH2), 6.54 (s, 1H, 
CH-thiophene), 7.02-8.56 (m, 8H, ArH), 9.07 (s, 1H, CH).13C NMR (DMSO-d6): δ 56.14, 
84.51, 103.58, 113.99, 116.16, 116.28, 117.55, 125.18, 126.35, 128.63, 129.10, 130.67, 131.12, 
135.01, 138.94, 140.86, 146.22, 150.38, 161.01, 163.45. MS, m/z (%): 406 (M+, 14). Anal. calcd 
for C21H15ClN4OS (406.89): C, 61.99; H, 3.72; N, 13.77; found: C, 61.84; H, 3.59; N, 13.61. 
 
5-Amino-3-(1-(3-chlorophenyl)-3-(4-methoxyphenyl)-1H-pyrazol-4-yl)-1-(quinolin-2-yl)-1H-
pyrazole-4-carbonitrile (3) 
 
In (30 mL) of dry ethanol, an equimolar (0.01 mol) of starting 1 and 2-hydrazinylquinoline were 
refluxed for 6 h. After cooling, the precipitate formed was purified from MeOH. Yield: 63%, 
m.p. 210-212 oC. IR (KBr, cm-1) ν: 3374 (NH2), 2214 (CN). 
1H NMR (DMSO-d6): δ 3.81 (s, 3H, 
OCH3), 7.05-7.99 (m, 14H, H-arom), 8.54 (s, 2H, NH2 exch.), 8.96 (s, 1H, CH). 
13C NMR 
(DMSO-d6): δ 56.72, 92.38, 101.35, 104.56, 113.67, 115.42, 115.64, 117.75, 123.58, 124.89, 
125.94, 126.18, 126.87, 128.16, 128.37, 128.92, 129.79, 130.47, 131.08, 135.01, 136.29, 
140.95, 143.82, 145.90, 153.72, 157.93, 161.76. MS, m/z (%): 517 (M+, 9). Anal. calcd for 
C29H20ClN7O (517.97): C, 67.25; H, 3.89; N, 18.93; found: C, 67.08; H, 3.72; N, 18.76. 
 
General method for synthesis of 2-alkyloxypyridine-3-carbonitrile derivatives 4a-h 
 
In an appropriate ethyl or methyl alcohol (15 mL) containing (0.003 mol) of potassium 
hydroxide, a mix of starting 1 (0.003 mol) and aryl ketones (0.003 mol) were stirred at ambient 
temperature for almost 67 h (monitored by TLC). The produced residue was purified with 
butanol. 
 
4-(1-(3-Chlorophenyl)-3-(4-methoxyphenyl)-1H-pyrazol-4-yl)-2-methoxy-6-(pyridine-3-yl)- 
pyridine-3-carbonitrile (4a). Yield: 46%, m.p. 234-236 oC. IR (KBr, cm-1) ν: 2227 (CN). 1H 
NMR (DMSO-d6): δ 3.79, 3.81 (2s, 6H, 2OCH3), 7.01-8.45 (m, 13H, ArH + H-5 pyridine), 8.95 
(s, 1H, CH). 13C NMR (DMSO-d6): δ 55.68, 56.12, 95.01, 102.84, 112.73, 114.58, 115.39, 
115.64, 119.22, 120.17, 123.62, 125.34, 126.41, 129.03, 131.10, 134.70, 135.08, 139.24, 
140.99, 146.13, 149.26, 152.04, 154.92, 157.46, 161.01, 164.10. MS, m/z (%): 493 (M+, 6). 
Anal. calcd for C28H20ClN5O2 (493.94): C, 68.08; H, 4.08; N, 7.18; found: C, 67.91; H, 3.89; N, 
7.04. 
 
4-(1-(3-Chlorophenyl)-3-(4-methoxyphenyl)-1H-pyrazol-4-yl)-2-ethoxy-6-(pyridine-3-yl)-pyridi- 
ne-3-carbonitrile (4b). Yield: 39%, m.p. 182-184 oC. IR (KBr, cm-1) ν: 2221 (CN). 1H NMR 
(DMSO-d6): δ 1.52 (t, 3H, J = 7.2 Hz, CH3), 3.80 (s, 3H, OCH3), 4.60 (q, 2H, J = 7.0 Hz, CH2), 
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7.01-8.52 (m, 13H, ArH + H-5pyridine), 8.95 (s, 1H, CH). 13C NMR (DMSO-d6): δ 14.49, 
56.05, 63.12, 94.78, 102.65, 112.80, 114.83, 115.40, 115.69, 118.02, 120.38, 123.55, 125.32, 
126.19, 128.67, 131.06, 134.48, 135.01, 138.60, 141.15, 145.85, 147.91, 149.98, 155.16, 
157.66, 161.01, 164.25. MS, m/z (%): 507 (M+, 4). Anal. calcd for C29H22ClN5O2 (507.97): C, 
68.57; H, 4.37; N, 13.79; found: C, 68.39; H, 4.20; N, 13.63. 
 
4-(1-(3-Chlorophenyl)-3-(4-methoxyphenyl)-1H-pyrazol-4-yl)-2-methoxy-6-(thiophen-2-yl)-pyri 
-dine-3-carbonitrile (4c). Yield: 28%; m.p. 243-245 oC. IR (KBr, cm-1) ν: 2223 (CN). 1H NMR 
(DMSO-d6): δ 3.78, 3.81 (2s, 6H, 2OCH3), 7.01-8.45 (m, 12H, ArH + H-5 pyridine), 8.95 (s, 
1H, CH). 13C NMR (DMSO-d6): δ 55.64, 56.08, 93.89, 104.50, 112.81, 114.63, 115.56, 116.04, 
118.21, 125.28, 125.79, 126.16, 127.11, 127.88, 128.46, 130.95, 133.82, 135.01, 139.68, 
142.31, 145.76, 153.14, 154.27, 161.01, 163.96.MS, m/z (%): 498 (M+, 2). Anal. calcd for 
C27H19ClN4O2S (498.98): C, 64.99; H, 4.08; N, 11.23; found: C, 64.80; H, 3.68; N, 11.07. 
 
4-(1-(3-Chlorophenyl)-3-(4-methoxyphenyl)-1H-pyrazol-4-yl)-2-ethoxy-6-(thiophen-2-yl)-pyrid- 
ine-3-carbonitrile (4d). Yield: 32%, m.p.147-149 oC, IR (KBr, cm-1) ν: 2219 (CN), 1H NMR 
(DMSO-d6): δ 1.49 (t, 3H, J = 6.8 Hz, CH3), 3.81 (s, 3H, OCH3), 4.62 (q, 2H, J = 6.8 Hz, CH2), 
7.01-8.55 (m, 12H, ArH + H-5 pyridine), 8.96 (s, 1H, CH). 13C NMR (DMSO-d6): δ 14.52, 
55.60, 63.24, 94.17, 104.45, 112.78, 114.71, 115.47, 115.95, 118.34, 124.90, 125.84, 126.10, 
127.12, 127.74, 128.54, 131.08, 134.29, 135.01, 140.18, 142.49, 147.02, 152.60, 155.13, 
161.01, 164.20.MS, m/z (%): 513 (M+, 4). Anal. calcd for C28H21ClN4O2S (513.01): C, 65.55; H, 
4.13; N, 10.92; found: C, 65.37; H, 3.98; N, 10.76. 
 
4-(1-(3-Chlorophenyl)-3-(4-methoxyphenyl)-1H-pyrazol-4-yl)-6-(4-hydroxyphenyl)-2-methoxy- 
pyridine-3-carbonitrile (4e). Yield: 31%, m.p. 257-259 oC; IR (KBr, cm-1) ν: 3412 (OH), 2220 
(CN). 1H NMR (DMSO-d6): δ 3.77, 3.80 (2s, 6H, 2OCH3), 7.01-8.65 (m, 13H, ArH + H-5 
pyridine), 8.98 (s, 1H, CH), 10.36 (s, 1H, OH). 13C NMR (DMSO-d6): δ 55.71, 56.10, 
94.16,104.45, 112.80, 114.65, 115.38, 115.85, 116.26, 118.34, 125.29, 128.44, 128.79, 129.04, 
130.67, 134.15, 135.01, 140.96, 146.03, 157.11, 157.24, 161.01, 164.22. MS, m/z (%): 509 (M+, 
6). Anal. calcd for C29H21ClN4O3 (508.96): C, 68.44; H, 4.16; N, 11.01; found: C, 68.28; H, 
3.98; N, 10.87. 
 
4-(1-(3-Chlorophenyl)-3-(4-methoxyphenyl)-1H-pyrazol-4-yl)-2-ethoxy-6-(4-hydroxyphenyl)-py- 
ridine-3-carbonitrile (4f). Yield: 37%, m.p. 192-194 oC. IR (KBr, cm-1) ν: 3398 (OH), 2226 
(CN). 1H NMR (DMSO-d6): δ 1.40 (t, 3H, J = 7.6 Hz, CH3), 3.81 (s, 3H, OCH3), 4.51 (q, 2H, J 
= 7.6 Hz, CH2), 7.01-8.70 (m, 13H, ArH + H-5 pyridine), 8.95 (s, 1H, CH), 10.45(s, 1H, OH). 
13C NMR (DMSO-d6): δ 14.82, 56.04, 63.20, 94.06, 104.56, 112.82, 114.54, 115.27, 115.93, 
116.10, 118.31, 125.17, 128.35, 128.90, 129.01, 130.74, 133.87, 135.01, 141.08, 145.97, 
157.05, 157.34, 161.01, 164.10; MS, m/z (%): 523 (M+, 7). Anal. calcd for C30H23ClN4O3 
(522.98): C, 68.90; H, 4.43; N, 10.71; found: C, 68.71; H, 4.25; N, 10.62. 
 
4-(1-(3-Chlorophenyl)-3-(4-methoxyphenyl)-1H-pyrazol-4-yl)-2-methoxy-6-(4-nitrophenyl)-pyr- 
idine-3-carbonitrile (4g). Yield: 39%, m.p. 262-264 oC. IR (KBr, cm-1) ν: 2221 (CN). 1H NMR 
(DMSO-d6): δ 3.78, 3.81 (2s, 6H, 2OCH3), 7.05-8.30 (m, 13H, ArH + H-5 pyridine), 8.95 (s, 
1H, CH). 13C NMR (DMSO-d6): δ 55.69, 56.15, 93.89, 104.34, 112.83, 114.60, 115.42, 115.90, 
118.24, 121.47, 125.37, 126.18, 128.52, 128.68, 130.71, 133.75, 135.01, 141.04, 143.12, 
145.85, 147.10, 153.02, 157.23, 161.01, 164.30. MS, m/z (%): 538 (M+, 5). Anal. calcd for 
C29H20ClN5O4 (537.95): C, 64.75; H, 3.75; N, 13.02; found: C, 64.58; H, 3.60; N, 12.89. 
 
4-(1-(3-Chlorophenyl)-3-(4-methoxyphenyl)-1H-pyrazol-4-yl)-2-ethoxy-6-(4-nitrophenyl)-pyrid- 
ine-3-carbonitrile (4h). Yield: 33%, m.p.178-180 oC; IR (KBr, cm-1) ν: 2228 (CN). 1H NMR 
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(DMSO-d6): δ 1.42 (t, 3H, J = 7.4 Hz, CH3), 3.80 (s, 3H, OCH3), 4.56 (q, 2H, J = 7.4 Hz, CH2), 
7.05-8.32 (m, 13H, ArH + H-5 pyridine), 8.95 (s, 1H, CH). 13C NMR (DMSO-d6): δ 14.76, 
56.09, 63.31, 94.15 104.45, 112.80, 114.57, 115.48, 115.78, 118.20, 121.64, 125.44, 126.10, 
128.49, 128.79, 130.62, 134.02, 135.01, 165.01. MS, m/z (%): 552 (M+, 8). Anal. calcd for 
C30H22ClN5O4 (551.98): C, 65.28; H, 4.02; N, 12.69; found: C, 65.09; H, 3.90; N, 12.52. 
 
N-(4-(1-(3-Chlorophenyl)-3-(4-methoxyphenyl)-1H-pyrazol-4-yl)-3-cyanothiophen-2-yl)-aceta- 
mide (5) 
 
In (7 mL) of acetic anhydride, starting 2 has been heatedfor 4 h under reflux. The solid product 
separated after being poured into cold water was gathered and purified from dioxane. Yield 
51%, m.p. 161-163 oC. IR, ν: 3446 (NH), 2218 (CN), 1658 (CO). 1H NMR (DMSO-d6): δ 2.38 
(s, 3H, CH3), 3.81 (s, 3H, OCH3), 7.05-7.56 (m, 10H, ArH + H-5 thiophene + NH exch.), 8.99 
(s, 1H, CH). 13C NMR (DMSO-d6): δ 22.54, 55.70, 92.46, 104.26, 114.61, 115.20, 115.59, 
118.09, 125.31, 126.52, 128.42, 130.69, 132.90, 135.04, 137.67, 140.78, 145.92, 148.16, 
150.73, 150.84, 161.01, 168.54. MS, m/z (%): 449 (M+, 8). Anal. calcd for C23H17ClN4O2S 
(448.92): C, 61.54; H, 3.82; N, 12.48; found: C, 61.35; H, 3.67; N, 12.33. 
 
5-(1-(3-Chlorophenyl)-3-(4-methoxyphenyl)-1H-pyrazol-4-yl)-2-methylthieno[2,3-d]pyrimidin-
4(3H)-one (6) 
 
In a mixture of HCl/AcOH (3:9 mL), starting 2 and/or derivative 5 (0.01 mol) was refluxed for 2 
h. The reaction mixture could cool down, the precipitation formed after it was pour in cold water 
was dried, and dioxan crystallized. Yield 60%, m.p. 192-194 oC, IR, ν: 3205 (NH), 1672 (CO). 
1H NMR (DMSO-d6): δ 2.41 (s, 3H, CH3), 3.79 (s, 3H, OCH3), 7.01-7.52 (m, 9H, ArH + H-5 
thiophene), 8.12 (s, 1H, NH ex.), 8.95 (s, 1H, CH). 13C NMR (DMSO-d6): δ 21.04, 55.76, 98.35, 
114.27, 115.46, 117.98, 125.09, 126.10, 126.89, 128.31, 129.93, 131.19, 135.01, 139.77, 
140.28, 140.87, 143.99, 153.68, 159.48, 160.14, 161.03. MS, m/z (%): 448 (M+, 11). Anal. calcd 
for C23H17ClN4O2S (448.92): C, 61.54; H, 3.82; N, 12.48; found: C, 61.41; H, 3.90; N, 12.39. 
 
General method for preparation of derivatives 7, 8 
 
A solution of starting 2 in (15 mL) of formamide or formic acid was reflux for 3-4 h. After 
cooling, the solid produced was washed and AcOH-crystallized. 
 
5-(1-(3-Chlorophenyl)-3-(4-methoxyphenyl)-1H-pyrazol-4-yl)thieno[2,3-d]pyrimidin-4-amine 
(7). Yield 60%, m.p. >300 oC. IR, ν: 3470, 3236 (NH2). 
1H NMR (DMSO-d6): δ 3.79 (s, 3H, 
OCH3), 7.05-7.45 (m, 9H, ArH + H-5 thiophene), 8.12 (s, 1H, H-2pyrimidine), 8.34 (s, 2H, 
NH2), 8.95 (s, 1H, CH). 
13C NMR (DMSO-d6): δ 55.63, 102.85, 114.59, 115.68, 118.22, 121.46, 
123.96, 125.18, 126.48, 128.37, 130.74, 133.15, 134.99, 140.69, 141.90, 143.89, 146.13, 
156.21, 158.02, 161.03. MS, m/z (%): 433 (M+, 11). Anal. calcd for C22H16ClN5OS (433.91): C, 
60.90; H, 3.72; N, 16.14; found: C, 60.72; H, 3.58; N, 15.97. 
 
5-(1-(3-Chlorophenyl)-3-(4-methoxyphenyl)-1H-pyrazol-4-yl)thieno[2,3-d]pyrimidin-4(3H)-one 
(8). Yield 57%, m.p. >300 oC. IR, ν: 3195 (NH), 1667 (CO). 1H NMR (DMSO-d6): δ 3.81 (s, 
3H, OCH3), 7.05-7.43 (m, 9H, ArH + H-5 thiophene), 8.14 (s, 1H, H-2 pyrimidine), 8.95 (s, 1H, 
CH), 12.36 (s, 1H, NH). 13C NMR (DMSO-d6): δ 55.79, 102.60, 114.67, 115.53, 118.10, 
125.38, 125.95, 127.14, 128.46, 130.62, 132.90, 135.10, 139.88, 140.98, 141.08, 145.34, 
147.01, 159.87, 158.02, 161.01, 161.23.MS, m/z (%): 435 (M+, 11). Anal. calcd for 
C22H15ClN4O2S (434.9): C, 60.76; H, 3.48; N, 12.88; found: C, 60.57; H, 3.29; N, 12.70. 
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1-(4-(1-(3-Chlorophenyl)-3-(4-methoxyphenyl)-1H-pyrazol-4-yl)-3-cyanothiophen-2-yl)-3-
phenylthiourea (9) 
 
In absolute ethanol (30 mL) containing (0.5 mL) of TEA, an equimolar mix (0.01 mol) of 
compound 2 and phenyl isothiocyanate were reflux for 5 h. The solid produced was methanol 
crystallized. Yield 70%, m.p. 238-240 oC. IR, ν: 3428, 3190 (2NH), 2210 (CN). 1H NMR 
(DMSO-d6): δ 3.81 (s, 3H, OCH3), 4.45 (s, 1H, NH), 6.90-7.49 (m, 14H, ArH + H-5 thiophene), 
8.95 (s, 1H, CH), 11.26 (s, 1H, NH). 13C NMR (DMSO-d6): δ 55.74, 102.86, 110.46, 114.53, 
115.26, 115.65, 118.29, 123.98, 125.16, 125.94, 126.48, 128.54, 129.03, 129.14, 130.77, 
133.62, 134.99, 136.89, 139.25, 140.85, 143.67, 146.08, 161.01, 182.35. MS, m/z (%): 542 (M+, 
17). Anal. calcd for C28H20ClN5OS2 (542.07): C, 62.04; H, 3.72; N, 12.92; found: C, 61.91; H, 
3.56; N, 12.79. 
RESULTS AND DISCUSSION 
Chemistry 
 
The synthetic routes to pyrazoles 2-9 have been identified in (Schemes 1 and 2). The starting 
ylidenemalononitrile 1 treated in basic conditions with sulfur to provide 2-aminothiophene-3-
carbonitrile derivative 2. Compound 2 showed two characteristic bands at 3386 and 2210 cm-1 
corresponding to amino and nitrile functions, whereas the 1H NMR spectrum exhibited two 
singlets peaks at δ 4.52 and 6.54 ppm for the amino protons and H-5 of thiophene ring. Also, 
peaks at δ 84.51, 103.58, 150.38 and 163.45 ppm proved C-5, C-3, C-2 and C-4 of the new 
thiophene ring in the 13C NMR spectrum. On the other hand, the starting 1 reacted with 2-
hydrazinylquinoline to afford 5-amino-4-cyano-3-aryl-pyrazole derivative 3. The later 
compound showed two different bands at 3374 and 2214 cm-1 belonging to amino and cyano 
functions, meanwhile 1H NMR spectrum showed two singlets at δ 3.81 and 8.54 ppm referred to 
  
RCOCH
3
R'OH, KOH
 
Scheme 1. Synthesis of compounds 2, 3 and 4a-h. 
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methoxy and amino protons. Furthermore, the precursor 1 condensed with various aryl ketones 
according to Michael addition to provide the desired 2-alkyloxy pyridine-3-carbonitriles 4a-h 
(Scheme 1). The later products exhibited strong bands in the range of 2219-2228 cm-1 referred 
to nitrile function in the IR spectrum. Also, the appearance of peaks corresponding to alkoxide 
in 1H NMR spectrum confirming the cyclization form of pyridine moiety. Moreover, 13C NMR 
and MS confirmed the carbons at their expected regions and molecular formula of the title 
products. 
The key intermediate 2 was reacted with acetic anhydride to afford acyclic 3-cyanothiophen-
2-acetamide derivative 5. Compounds 2 or 5 treated with HCl/AcOH mixture (3:9 mL) to afford 
the pyrimidinone derivative 6. 1H NMR spectrum showed peaks for methyl and amino protons 
at δ 2.41, 8.12 ppm besides peaks appeared in the 13C NMR spectrum attributed to methyl and 
carbonyl groups at δ 21.04, 160.14 ppm. 
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Scheme 2. Synthesis of compounds 5-9. 
 
The desired thieno[2,3-d]pyrimidine derivatives 7, 8 could be achieved through cyclization 
reaction ofcompound 2 and formamide or formic acid. Compound 7 indicated the disappearance 
of nitrile band and appearance of new bands for the amino group at 3470, 3236 cm-1 in IR 
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spectrum, besides two singlet peaks for H-2 of pyrimidine and amino protons at δ 8.12 and 8.34 
ppm respectively in the 1HNMR spectrum. In the same time, compound 8 reveled lack of nitrile 
function with the appearance of new bands for amino and carbonyl groups. 
Furthermore, the key intermediate 2 was reacted with phenyl isothiocyanate to give the 
corresponding 3-cyanothiophen-2-phenylthiourea derivative 9 (Scheme 2). New bands were 
shown in the later compound 9 at 3428, 3190 and 2210 cm-1 due to (2NH) and (CN) functions in 
IR spectra, besides two singlets signals appeared at δ 4.45 and 11.26 ppm assigned to D2O-
exchangeable (2NH) protons in the 1H NMR spectrum. 
 
Analgesic activity evaluation 
 
The analgesic profile of compounds 2–9, acquired from hot plate test and acetic acid induced 
writhing test was performed using the techniques previously mentioned [30,31]. The findings 
are presented in (Tables 1 and 2).  
The compounds tested showed remarkable analgesic effects in the hot plate and writhing 
assays in mice. Regarding central analgesic activity (hot plate test): The latency of the examined 
products improved compared to fundamental levels by oral administration. The resulting data 
revealed 4d, 4e, 4f, 4g, 4h, 6, 7 and 9 derivatives showing significant analgesic activity (70-159 
%) increase in pain threshold after 90 min following the administration. Compound 7 which 
contains the fused pyrimidine moiety showed highest core analgesic characteristics (159.6%) at 
90 min, which was statistically equipotent to the control drug (174.6%). The central analgesic 
properties of the active products next 90 min, sorted in descending way, were 159.6, 115.28, 
102.1, 93.8, 85.6, 84.2, 80.1, 76.0 and 70.5 % for derivatives 7, 4g, 4e, 4f, 4d, 3, 4, 4h and 9, 
respectively, comparable to the reference tramadol (Table 1). 
 
Table 1. Central analgesic activity of synthesized compounds in mice. 
 
90 min 60 min 30 min 0 min 
Reaction 
time (s) 
Compds Protection 
(%) 
Reaction 
time (s) 
Protection 
(%) 
Reaction 
time (s) 
Protection 
(%) 
Reaction 
time (s) 
0 14.6±0.58 ǂ 0 14.5±0.45 ǂ 0 12.8±0.91 ǂ 12.7±1.04 Control 
44.5 21.1±1.10 ǂ 6.2 15.4±0.81 ǂ 0.8 12.6±1.00 ǂ 10.3±0.80 2 
84.2 26.9±2.38 *ǂ 65.5 24.0±1.12 *ǂ 79.5 22.8±0.97 *ǂ 11.6±0.65 3 
53.4 22.4±0.91 ǂ 25.5 18.2±0.94 ǂ 19.6 15.2±0.20 ǂ 10.4±0.79 4a 
42.4 20.8±1.57 *ǂ 4.8 15.2±1.04 ǂ 1.6 12.9±1.19 ǂ 11.0±0.38 4b 
33.6 19.5±1.00 ǂ 32.4 19.2±0.36 ǂ 9.4 13.9±0.42 ǂ 10.6±0.41 4c 
85.6 27.1±2.14 *ǂ 55.9 22.6±1.35 *ǂ 44.0 18.3±0.85 *ǂ 11.1±0.90 4d 
102.1 29.5±2.42 *ǂ 45.5 21.1±2.09 *ǂ 45.7 18.5±1.00 *ǂ 10.5±0.54 4e 
93.8 28.3±0.98 *ǂ 65.5 24.0±0.87 *ǂ 50.4 19.1±1.12 *ǂ 11.2±0.61 4f 
115.8 31.5±1.40 * 96.6 28.5±1.45 * 96.0 24.9±0.51 * 10.7±0.86 4g 
76.0 25.7±2.05 *ǂ 55.9 22.6±0.67 *ǂ 24.4 15.8±0.45 ǂ 12.1±0.57 4h 
58.2 23.1±2.67 ǂ 73.1 25.1±1.00 *ǂ 38.6 17.6±1.00 ǂ 10.1±0.48 5 
80.1 26.3±1.04 *ǂ 33.1 19.3±1.23 ǂ 25.2 15.9±0.56 ǂ 11.5±0.69 6 
159.6 37.9±0.37 ǂ 117.2 31.5±0.10 ǂ 105.5 26.1±1.23 *ǂ 10.4±0.82 7 
35.6 19.8±0.87 *ǂ 43.4 20.8±2.05 ǂ 33.8 17.0±1.34 *ǂ 10.0±0.94 8 
70.5 24.9±2.51 ǂ 75.1 25.4±0.90 *ǂ 59.8 20.3±0.73 * 10.1±1.02 9 
174.6 40.1±2.28 * 127.5 33.0±1.00 * 131.2 29.6±1.57 * 10.8±0.53 Tramadol 
*p < 0.05: Statistically significant from control (Dunnett's test). ǂp < 0.05: statistically significant from tramadol 
(Dunnett's test). 
 
According to acetic acid induced writhing test, peripheral analgesic activity was found in all 
the compounds examined versus acetic acid induced writhing conduct related to vehicle-treated 
mice. Aconsiderable decrease in the writhing response was noticed in compounds 4e (70.29%), 
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4g (75.25) and 7 (82.43%). In addition, the peripheral analgesic impact of pyrimidine analog 7 
(82.43%) showed superior to those of aspirin (78.47%) (Table 2, Figure 2). 
 
Table 2. Peripheral analgesic activity of synthesized compounds in mice. 
 
Compds No. of writhes 
/20 min 
Protection (%) Compds No. of writhes 
/20 min 
Protection 
(%) 
Control 80.8±4.5ǂ ----- 4g 20.8±1.3* 74.25 
2 28.4±2.1* 64.85 4h 28.6±2.9* 64.60 
3 34.6±1.4*ǂ 57.18 5 38.2±1.7* 52.72 
4a 41.2±3.2*ǂ 49.00 6 31.5±2.1*ǂ 61.01 
4b 39.8±1.8*ǂ 50.74 7 14.2±1.0*ǂ 82.43 
4c 36.5±1.8*ǂ 54.83 8 43.6±2.9*ǂ 46.04 
4d 27.1±2.5* 66.46 9 27.3±2.5*ǂ 66.21 
4e 24.0±1.6* 70.29 Aspirin 17.4±1.6* 78.47 
4f 25.3±3.3*ǂ 68.69    
 
 
 
Figure 2. Peripheral analgesic activity of the synthesized products 2-9 in mice. 
 
 
CONCLUSION 
 
New pyrazole derivatives including thiophene, 2-alkyloxy-pyridine and thieno[2,3-d]pyri- 
midines have been synthesized and analgesical activities and have been performed and 
discussed. The  products  acquired  inhibited  the  restriction  of  acetic  acid  and  the  response 
of hot  plate  device  relative to conventional aspirin  control. Our results suggest that it is 
favorable to analgesic activity to incorporate substituted pyridine and fused thieno[2,3-
d]pyrimidinemoieties with pyrazole backbone. 
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